Does the media favor ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat ADMA Biologics' score of -0.11 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADMA or ALLO?

In the previous week, ADMA Biologics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for ADMA Biologics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.01 beat ADMA Biologics' score of -0.11 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, TGTX or ADMA?

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 14.12 $447.18M $2.74 20.76 ADMA Biologics $510.17M 4.00 $146.93M $0.70 13.01

Does the media favor TGTX or ADMA?

In the previous week, TG Therapeutics had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for TG Therapeutics and 3 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 0.86 beat ADMA Biologics' score of -0.11 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SYRE or ADMA?

In the previous week, Spyre Therapeutics had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Spyre Therapeutics and 3 mentions for ADMA Biologics. Spyre Therapeutics' average media sentiment score of 0.95 beat ADMA Biologics' score of -0.11 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADMA or IMVT?

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. Immunovant's average media sentiment score of 0.60 beat ADMA Biologics' score of -0.11 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADMA Biologics (ADMA) Competitors

$9.11 +0.16 (+1.79%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.15 +0.04 (+0.49%)

As of 09/18/2026 07:32 PM Eastern

Compare

ADMA vs. ACAD, ALLO, TGTX, SYRE, and IMVT

Should you buy ADMA Biologics stock or one of its competitors? ADMA Biologics's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

ACADIA Pharmaceuticals presently has a consensus price target of $34.36, suggesting a potential upside of 25.91%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 104.90%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01

ACADIA Pharmaceuticals has a net margin of 33.42% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
ADMA Biologics	32.98%	40.17%	26.97%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat ADMA Biologics' score of -0.11 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 12 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

ADMA Biologics currently has a consensus target price of $18.67, indicating a potential upside of 104.90%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 391.12%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, ADMA Biologics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for ADMA Biologics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.01 beat ADMA Biologics' score of -0.11 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A

ADMA Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

TG Therapeutics currently has a consensus price target of $63.00, indicating a potential upside of 10.78%. ADMA Biologics has a consensus price target of $18.67, indicating a potential upside of 104.90%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

TG Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to ADMA Biologics' net margin of 32.98%. TG Therapeutics' return on equity of 73.49% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, TG Therapeutics had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for TG Therapeutics and 3 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 0.86 beat ADMA Biologics' score of -0.11 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	14.12	$447.18M	$2.74	20.76
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TG Therapeutics beats ADMA Biologics on 13 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ADMA Biologics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,917.51	-$155.20M	-$1.95	N/A
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01

Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Spyre Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, Spyre Therapeutics had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Spyre Therapeutics and 3 mentions for ADMA Biologics. Spyre Therapeutics' average media sentiment score of 0.95 beat ADMA Biologics' score of -0.11 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics currently has a consensus target price of $109.69, suggesting a potential upside of 21.54%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 104.90%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Spyre Therapeutics beats ADMA Biologics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Immunovant?

ADMA Biologics (NASDAQ:ADMA) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

ADMA Biologics currently has a consensus price target of $18.67, suggesting a potential upside of 104.90%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 19.08%. Given ADMA Biologics' higher possible upside, equities research analysts plainly believe ADMA Biologics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

ADMA Biologics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. Immunovant's average media sentiment score of 0.60 beat ADMA Biologics' score of -0.11 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a net margin of 32.98% compared to Immunovant's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Immunovant	N/A	-69.59%	-62.49%

Summary

ADMA Biologics beats Immunovant on 10 of the 14 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.00B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	13.01	14.30	275.79	25.40
Price / Sales	4.00	1,415.50	695.58	114.44
Price / Cash	13.68	110.75	77.42	51.66
Price / Book	4.53	15.45	10.46	6.33
Net Income	$146.93M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.30%	-1.21%	0.59%	1.12%
1 Month Performance	-9.35%	-4.42%	-2.01%	-2.67%
1 Year Performance	-42.74%	37.81%	18.09%	6.01%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	3.1326 of 5 stars	$9.11 +1.8%	$18.67 +104.9%	-43.6%	$2.00B	$510.17M	13.01	647	High Trading Volume
ACAD ACADIA Pharmaceuticals	4.436 of 5 stars	$27.52 -1.1%	$34.36 +24.9%	+10.3%	$4.80B	$1.07B	12.40	798	Positive News
ALLO Allogene Therapeutics	1.7512 of 5 stars	$1.78 flat	$8.30 +366.3%	+39.7%	$614.97M	$4.64M	N/A	152
TGTX TG Therapeutics	3.3773 of 5 stars	$54.00 +0.2%	$63.00 +16.7%	+74.4%	$8.25B	$616.29M	19.71	399
SYRE Spyre Therapeutics	2.7412 of 5 stars	$90.80 +0.2%	$109.69 +20.8%	+489.1%	$7.97B	N/A	N/A	112

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, TGTX, SYRE, and IMVT

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Summary

How does ADMA Biologics compare to Spyre Therapeutics?

Summary

How does ADMA Biologics compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, TGTX, SYRE, and IMVT

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Which has more volatility & risk, ACAD or ADMA?

Do analysts prefer ACAD or ADMA?

Which has preferable valuation & earnings, ACAD or ADMA?

Is ACAD or ADMA more profitable?

Do institutionals and insiders hold more shares of ACAD or ADMA?

Does the media favor ACAD or ADMA?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Do analysts recommend ADMA or ALLO?

Does the media prefer ADMA or ALLO?

Do insiders & institutionals have more ownership in ADMA or ALLO?

Which has better earnings and valuation, ADMA or ALLO?

Which has more volatility & risk, ADMA or ALLO?

Is ADMA or ALLO more profitable?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Do analysts prefer TGTX or ADMA?

Which has more risk and volatility, TGTX or ADMA?

Is TGTX or ADMA more profitable?

Does the media favor TGTX or ADMA?

Which has stronger valuation and earnings, TGTX or ADMA?

Do insiders and institutionals believe in TGTX or ADMA?

Summary

How does ADMA Biologics compare to Spyre Therapeutics?

Do institutionals & insiders believe in SYRE or ADMA?

Which has better earnings and valuation, SYRE or ADMA?

Which has more risk and volatility, SYRE or ADMA?

Is SYRE or ADMA more profitable?

Does the media favor SYRE or ADMA?

Do analysts rate SYRE or ADMA?

Summary

How does ADMA Biologics compare to Immunovant?

Do analysts recommend ADMA or IMVT?

Which has stronger valuation and earnings, ADMA or IMVT?

Which has more volatility and risk, ADMA or IMVT?

Do institutionals and insiders hold more shares of ADMA or IMVT?

Does the media refer more to ADMA or IMVT?

Is ADMA or IMVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools